Slide 1: Investor Presentation August 2023
Investor Presentation August 2023
Slide 2: Forward Looking Statements
Forward Looking Statements NeurAxis, Ine, (*NeurAxis") is offering shares of commen stock (the “Securities”) in a public offering (the “Offering"). The proceeds of the Offering, if completed, are intended primatily to be used for sales and marketing activities, research and development, certain paym
Slide 3: NeurAxis PENFS: First FDA Cleared Treatment for Pediatric FAP/IBS
NeurAxis PENFS": First FDA Cleared Treatment for Pediatric FAP/IBS? Unique, Innovative Product Large Global Market with Significant Supported by Clinical Evidence Unmet Need + $30B+ TAM? for target pipeline indications + $9B+ TAN for target pediatric indications (near- to-mid term) + $2184 TAN® for
Slide 4: 1st Half 2023 Highlights
1st Half 2023 Highlights +» Expanded insurance policy coverage *» Submitted CPT CAT | application * Coverage extends to 4.75M lives from 4M at the + Launched internal prior authorization team to end of 2022 support and strengthen account utilization * Notable Plans: * Received FDA feedback earlier t
Slide 5: Percutaneous Electrical Nerve Field Stimulation (PENFS)
Percutaneous Electrical Nerve Field Stimulation (PENFS) | How Does Neuromodulation Work? Teigeminal (V) Facial (Ul) N “Glossophanyngeal — ‘Vagus 00 1.Access *———- 2.Stimulate *———~ 3.Change Direct access to central Stimulation reduces firing Induces changes in brain nervous system (CNS) of amygdala
Slide 6: Established Technology with Demonstrated Safety and Efficacy
Established Technology with Demonstrated Safety and Efficacy What is IB-Stim™ * PENFS system intended for patients 11-18 years of age with functional abdominal FDA De Novo pain (FAP) associated with IBS Clearance * Aids in pain reduction via neuromodulation to branches of Cranial Nerves (V,VII,IX an
Slide 7: IB-Stim Advantages Over Traditional Care
IB-Stim™ Advantages Over Traditional Care Traditional Care FDA Indicated Ko RD AVAr eT) Treatments Rx often Percutaneous Electical Nerve Fie Stimulation for table Bowel Containing FDA Syndrome Black Box Labels Suicidal Ideation, Non-Drug ainszeTe Alternative rene Localized Skin pa Depression, & Irri
Slide 8: Artificial Intelligence to IB-Stim
Artificial Intelligence to IB-Stim™ Select Artificial Intelligence will analyze large datasets, allowing for the automated diagnosis of FAPDs Select patients via EMR with a higher likelihood of response to IB-Stim™ Predict response to treatment using IB-Stim™ Obviate the need for referral to pediatr
Slide 9: $30B+ Total Addressable U.S. Market for Pipeline Indications
$30B+ Total Addressable U.S. Market for Pipeline Indications Near-to-mid term Target Mid-term Target $18 en \ $3B 328 Oye coneusen vom $9B+ 398 jaf Scie Pediatric vomiting TAM* Fare $28 Nausea Why Pediatrics? * Significant unmet need * Lack of FDA approved treatment options * Single call point for f
Slide 10: IB-Stim Research — By the Numbers
IB-Stim™ Research — By the Numbers Current Publications Types of Studies & Double Blind Long-Term ES Placebo Controlled Data P Quality of Real World Registry Data Life Data Clinical Data J\.. Head-to-Head Research vs. SoC @ Health Economic Study 10 cS
Slide 11: Competitive Landscape
m™ Competitive Landscape Antidepressants Adult Use (Peripherally Acting at the Gut Level) 1B-stim™ Psychological pritriptyline Citalopram Amitiza Linzess Trulance Viberzi Therapy FDA Approved for IBS in oS y Children and Adolescents Improves Functional Disability v v ORDO REUEES v Y v v Better Than
Slide 12: FDA Pipeline Indications
FDA Pipeline Indications Pre-Clinical/ Human Human 510k / De a Non-Human Clinical Trial Clinical Novo FDA Target Launch Indication Testing Design Submission Chemotherapy-Induced Nausea & ‘Vomiting (Pediatric) Cyclic Vomiting Syndrome (Pediatric)
Slide 13: Go-To-Market Strategy
Go-To-Market Strategy 2023 Coverage oa Total # Lives covered 4 plans 4.75M. BCBS of Massachusetts 3M BCBS of South Carolina 750k BCBS of Nebraska 700k Quartz of Wisconsin 300k Actively leveraging publications to expand coverage Expecting Society position paper and guideline changes supporting IB-Sti
Slide 14: NeurAxis IP Portfolio issued and pending patents
NeurAxis IP Portfolio 8 issued and 18 pending patents = Device = Method U.S. IP runs through 2039 for now International IP in process Freedom to operate —~, 7 NeurAxis
Slide 15: Key Achievements and Milestones
Key Achievements and Milestones 2012 2017 ‘Company Founded Lancet Publication “CAT CPT Code Submission (B-Stim™ RCT!) BOBS SC Expected FDA Pediatric Indication Expansion to Functional Nausea *BCBS NE & Quartz Wisconsin Additional Academic Society american Academy of Pediatrics __ SUPPort ‘Written Su
Slide 16: Management Team
16 Management Team Brian Carrico Chief Executive Officer, Board Member HEE st. june Mepicat ) Dr. Adrian Miranda Chief Medical Officer BA MEDICAL COLLEGE. OF WISCONSIN Children’s Hospital of Wists © & HOG John Seale Chief Financial Officer Dan Clarence Dr. Tom Carrico Chief Operating Officer Dr. Chr
Slide 17: Key Investment Highlights
Key Investment Highlights Large Global Market with Significant Unmet Need + $30B+ TAM for target pipeline indications ‘+ $98+ TAM? for target pediatric indications (near-to-mid term) + $21B+ TAM fr target adult indications (id term) + Large unmet cinical need: high refractory, offiabel pharmacologic